About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RVNC DEADLINE ALERT: Kirby McInerney LLP Alerts Revance Therapeutics, Inc. Investors of Important Lead Plaintiff Deadline in Class Action Lawsuit

By: via Business Wire

The law firm of Kirby McInerney LLP alerts investors of the imminent March 4, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ: RVNC) securities between February 29, 2024, through December 6, 2024 (“the Class Period”). The firm encourages investors to contact the firm as soon as possible to be appointed lead plaintiff.

[LEARN MORE ABOUT THE CLASS ACTION]

Prior to the Class Period, in January 2020, Revance entered into a distribution agreement (the “Distribution Agreement”) with Teoxane SA (“Teoxane”), pursuant to which Teoxane granted Revance the exclusive right to import, market, promote, sell, and distribute Teoxane’s line of Resilient Hyaluronic Acid dermal fillers, in exchange for 2,500,000 shares of Revance common stock. In addition, under the Distribution Agreement, Revance is required to meet certain minimum purchase obligations and certain minimum expenditure requirements and either party may terminate the Distribution Agreement in the event of “a material breach by the other party.”

In August 2024, Revance and Crown Laboratories, Inc. (“Crown”), a privately held marketer and manufacturer of skincare products, jointly announced that they had entered into a merger agreement (the “Merger Agreement”). Under the terms of the Merger Agreement, Crown would commence a tender offer (the “Tender Offer”) to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a total enterprise value of $924 million.

On September 23, 2024, Revance disclosed in an SEC filing that it “received a notice to remedy alleged material breaches, including breaches of the maximum level of buffer stock and required efforts to promote and sell Teoxane products, under the Company’s exclusive distribution agreement with Teoxane SA.” Due to the dispute with Teoxane, Revance advised that Crown’s Tender Offer had been delayed until at least October 4, 2024. On this news, the price of Revance shares declined by $0.45 per share, or 7.66%, from $5.81 per share on September 20, 2024, to close at $5.36 on September 23, 2024.

Then, on December 9, 2024, Revance disclosed in an SEC filing that Crown and Revance had amended their merger agreement, and that Crown would shortly commence a tender offer to acquire all outstanding shares of Revance’s common stock for $3.10 per share in cash – a reduction of over 50% from the previously-announced purchase price. On this news, the price of Revance shares declined by $0.79 per share, or approximately 20.68%, from $3.82 per share on December 6, 2024, to close at $3.03 on December 9, 2024.

The complaint alleges that defendants, throughout the Class Period, made false and/or misleading statements and/or failed to disclose that: (1) Revance was in material breach of the Distribution Agreement; (2) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; and (3) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended.

If you purchased or otherwise acquired Revance securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT FORM]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

More News

View More
Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
Via MarketBeat
Topics Economy
Tickers HIMS
After the Fed's Rate Cut, PNC Could See a Mortgage Refinance Boom
Via MarketBeat
Topics Economy
Tickers PNC
AIRO Group's Pullback: An Undervalued Growth Opportunity?
Via MarketBeat
Topics Supply Chain
Tickers AIRO
Caterpillar Stock Hits All-Time High—Is There More Room to Run?
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
Tickers CAT
Berkshire-Backed Lennar Slides After Weak Q3 Earnings
Via MarketBeat
Topics ETFs
Tickers BRK-A BRK-B LEN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.